LPL and type 2 diabetes mellitus: This is consistent with others studies that show PPARα inhibition/mutations are associated with hypertriglyceridaemia and elevated hepatic triglycerides and PPARα agonists are effective in treating dyslipidaemia in type 2 diabetes patients and drugs that elevate hepatic lipoprotein lipase do so via PPARα activation [68].